Richard Scott Struthers - Nov 9, 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Nov 9, 2023
Transactions value $
$95,500
Form type
4
Date filed
11/13/2023, 04:33 PM
Previous filing
Nov 6, 2023
Next filing
Feb 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $95.5K +50K +36.89% $1.91* 186K Nov 9, 2023 Direct
holding CRNX Common Stock 631K Nov 9, 2023 By Family Trust 1
holding CRNX Common Stock 1K Nov 9, 2023 By Spouse
holding CRNX Common Stock 90K Nov 9, 2023 By Family Trust 2
holding CRNX Common Stock 90K Nov 9, 2023 By Family Trust 3
holding CRNX Common Stock 90K Nov 9, 2023 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Incentive stock option (Right to Buy) Options Exercise $0 -50K -33.05% $0.00 101K Nov 9, 2023 Common Stock 50K $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.